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Abstract
Background: In spite of a large amount of studies in anesthetized animals, isolated hearts, and in
vitro cardiomyocytes, to our knowledge, myocardial function was never studied in conscious
diabetic rats. Myocardial performance and the response to stress caused by dobutamine were
examined in conscious rats, fifteen days after the onset of diabetes caused by streptozotocin (STZ).
The protective effect of insulin was also investigated in STZ-diabetic rats.
Methods: Cardiac contractility and relaxation were evaluated by means of maximum positive
(+dP/dtmax) and negative (-dP/dtmax) values of first derivative of left ventricular pressure over time.
In addition, it was examined the myocardial response to stress caused by two dosages (1 and 15
μg/kg) of dobutamine. One-way analysis of variance (ANOVA) was used to compare differences
among groups, and two-way ANOVA for repeated measure, followed by Tukey post hoc test, to
compare the responses to dobutamine. Differences were considered significant if P < 0.05.
Results: Basal mean arterial pressure, heart rate, +dP/dtmax and -dP/dtmax were found decreased
in STZ-diabetic rats, but unaltered in control rats treated with vehicle and STZ-diabetic rats treated
with insulin. Therefore, insulin prevented the hemodynamic and myocardial function alterations
observed in STZ-diabetic rats. Lower dosage of dobutamine increased heart rate, +dP/dtmax and -
dP/dtmax only in STZ-diabetic rats, while the higher dosage promoted greater, but similar, responses
in the three groups. In conclusion, the results indicate that myocardial function was remarkably
attenuated in conscious STZ-diabetic rats. In addition, the lower dosage of dobutamine uncovered
a greater responsiveness of the myocardium of STZ-diabetic rats. Insulin preserved myocardial
function and the integrity of the response to dobutamine of STZ-diabetic rats.
Conclusion:  The present study provides new data from conscious rats showing that the
cardiomyopathy of this pathophysiological condition was expressed by low indices of contractility
and relaxation. In addition, it was also demonstrated that these pathophysiological features were
prevented by the treatment with insulin.
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Background
Besides increased incidence of autonomic neuropathy
and coronary artery disease, diabetes has been considered
an independent risk for myocardial dysfunction [1,2].
It is well documented in experimental diabetes that both
left ventricular diastolic [3,4] and systolic dysfunction
[5,6] are attributed to diabetic cardiomyopathy, as usually
seen under clinical condition [1,3].
A deleterious effect of diabetes on cardiac performance
has been well documented in isolated heart preparation
[7], isolated cardiomyocytes [5] and intact anesthetized
animals [8]. Recently, Yoon et al. [7] showed in chronic
diabetic rats, under anesthesia, a decrease of both myocar-
dial contractility and relaxation. However, in spite of a
large amount of studies in anesthetized animals, isolated
hearts, and in vitro cardiomyocytes, to our knowledge,
myocardial function was never studied in conscious dia-
betic rats. Besides myocardial dysfunction, it is well
known that experimental diabetes affects hemodynamic
parameters such as heart rate and arterial pressure [9,10].
Myocardial stress produced by dobutamine is a useful tool
for evaluating cardiac events in humans [11] and experi-
mental animals [8]. This β1-adrenergic receptor agonist
promotes an increase in both contractility and heart rate.
Therefore, dobutamine was used to evaluate the degree of
attenuation of the inotropism, lusitropism and
chronotropism exhibited by STZ-diabetic rats.
It is well documented that insulin can prevent, or revert, a
number of outcomes caused by experimental diabetes
[12,13]. In fact, insulin normalizes not only blood glu-
cose levels [12], but most of the metabolic parameters of
diabetic rats [14,15]. Studies from isolated papillary mus-
cle [12] and isolated heart preparations [16] showed that
insulin reversed, or prevented, contractile dysfunction in
diabetic rats. Therefore, a protocol was carried out to
examine the protective effect of this hormone on the
hemodynamic and myocardial function of STZ-diabetic
rats.
In the present study, STZ was used to produce experimen-
tal diabetes, such that myocardial contractility and relaxa-
tion was examined in conscious rats. From the
methodological point of view cardiac function was indi-
rectly assessed by means of the first derivative of left ven-
tricular pressure over time, more specifically, the
maximum rate of isovolumic pressure development (+dP/
dtmax, an inotropic index) and the maximum rate of isovo-
lumic pressure decay (-dP/dtmax, a lusitropic index).
Hemodynamic parameters, such as heart rate and arterial
pressure were evaluated as well. Moreover, myocardial
stress test with dobutamine was used to evaluate the
degree of attenuation of myocardial performance of STZ-
diabetic rats. Finally, a protocol was carried out to exam-
ine the protective effect of insulin on the hemodynamic
and myocardial function of STZ-diabetic rats.
Methods
Experimental Diabetic Model
Male Wistar rats (~300 g) received a single injection of
STZ (50 mg/kg, dissolved in 0.01 M citrate buffer, pH 4.5)
into the penile vein, after a fasting overnight for approxi-
mately 12 hours. An equivalent volume (0.1 mL) of vehi-
cle (0.01 M citrate buffer, pH 4.5) was administered to
control rats. Development of diabetes was confirmed 72 h
later by the presence of hyperglycemia (> 350 mg/dL).
Half of STZ-diabetic rats was selected to receive daily
injection of insulin NPH (9 UI/kg/day, s.c.), starting 3
days after STZ injection. Blood glucose measurement
(Beckman Glucose Analyzer, Beckman Instruments Inc.,
Fullerton, EUA) was performed 3 and 15 days after STZ or
vehicle administration. The three groups were studied 15
days after the administration of STZ (n = 9), or vehicle (n
= 8), or STZ associated with insulin (n = 8).
Surgical Protocol
The animals were anesthetized with tribromoethanol
(250 mg/kg, i.p.) and the right common carotid artery was
isolated and indwelled with a PE50 polyethylene catheter,
whose tip was inserted into the left ventricle. Two other
polyethylene catheters (PE10 soldered to PE50) were
inserted into the femoral artery and vein for arterial pres-
sure recording and drug administration, respectively. The
catheters were exteriorized in the back of the neck. After
the surgical procedure the rats were placed in individual
cages for surgical recovery, during approximately 24 h,
with free access to food and tap water.
Blood Pressure and Left Ventricular Pressure Recording
On the day of the experiment, without the effect of
anesthesia, the animals were brought to the experimental
room with at least 30 min in advance, in order to adapt to
the laboratory. The arterial and ventricular catheters were
connected to pressure transducers (P23Gb, Statham, Hato
Hey, PR) and the signals were amplified (CL-615422-1,
Gould Instruments Systems, Inc., Valley View, USA) and
digitally sampled (1 kHz) on an IBM/PC equipped with
an analog to digital interface (DI-220, Dataq Instruments,
Akron, USA). During the recordings the rats were allowed
to move, freely, inside the cage.
Experimental Protocol
After 5 min of basal recording of arterial and left ventricu-
lar pressure, 1 and 15 μg/kg of dobutamine were adminis-
tered intravenously in a random sequence. Ten to 15 min
elapsed between each dosage.Cardiovascular Diabetology 2006, 5:26 http://www.cardiab.com/content/5/1/26
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All procedures used in the present study adhered to The
Guide for the Care and Use of Laboratory Animals pre-
pared by the National Academy of Sciences and published
by the National Institute of Health (NIH Publication n°
80-23, revised 1978), and the experimental protocols
used in this research were reviewed and approved by the
Committee of Ethics in Animal Research of the School of
Medicine of Ribeirão Preto, University of São Paulo.
Data Analysis
Pulsatile AP recordings were processed by a computer
software (Advanced CODAS/Windaq, Dataq Instruments,
Akron, USA) that applies an algorithm to detect inflection
points of a periodic waveform determining, beat-by-beat,
values of systolic and diastolic pressures. Heart rate was
calculated every cardiac cycle from the interval between
successive values of diastolic arterial pressure. The first
derivative of left ventricular pressure was calculated, and
the maximum rate of isovolumic pressure development
(+dP/dtmax) and the maximum rate of isovolumic pres-
sure decay (-dP/dtmax) values were used as indices of con-
tractility and relaxation, respectively. The response of the
parameters investigated, arterial pressure, heart rate, +dP/
dtmax and -dP/dtmax, to dobutamine, were calculated by
the difference between the maximal response and the
baseline value immediately before dobutamine adminis-
tration.
Statistical Analysis
Data are reported as mean ± SEM. One-way analysis of
variance (ANOVA) was used to compare differences
among groups, and two-way ANOVA for repeated meas-
ure, followed by Tukey post hoc test, to compare the
responses to dobutamine. Differences were considered
significant if P < 0.05.
Results
Weight and Blood Glucose
Table 1 shows weight and blood glucose levels of the three
groups studied. STZ-diabetic rats developed severe hyper-
glycemia associated with decreased body weight. On the
other hand, control rats and STZ-diabetic rats treated with
insulin exhibited normal weight gain and blood glucose
levels.
Hemodynamic and Cardiac Function Parameters
Table 2 shows baseline values of mean arterial pressure,
heart rate, +dP/dtmax and -dP/dtmax of the three groups
studied. STZ-diabetic rats show significant reduction of
these parameters, while control rats and STZ-diabetic rats
treated with insulin did not exhibit any alteration of these
parameters.
β1-Adrenergic Receptor Stimulation with Dobutamine
The responses of +dP/dtmax and -dP/dtmax to dobutamine
in the three groups studied are shown in Figure 1. STZ-dia-
betic rats exhibited a greater response of +dP/dtmax and -
dP/dtmax to 1 μg/kg of dobutamine as compared to control
rats, while insulin prevented this greater response. The
dosage of 15 μg/kg of dobutamine elicited a higher dP/dt
response in the three groups, as compared to the response
caused by 1 μg/kg, even though the response to 15 μg/kg
of dobutamine did not differ among the three groups.
Insulin did not affect the enhanced response to the higher
dosage of dobutamine, i.e 15 μg/kg of dobutamine.
The responses of heart rate and mean arterial pressure to
dobutamine, for the three groups, are shown in Figure 2.
Notice that 1 μg/kg of dobutamine elicited a greater
increase of heart rate in STZ-diabetic rats, while insulin
prevented this greater response. Figure 2 still shows simi-
lar increase of mean arterial pressure in the three groups,
without effect of insulin. On the other hand, 15 μg/kg elic-
ited a greater response of heart rate and mean arterial pres-
sure as compared to the responses of 1 μg/kg. However,
the amplified response of heart rate and mean arterial
pressure to 15 μg/kg did not differ among the three
groups, and insulin did not affect the amplified response
to this higher dosage of dobutamine.
Discussion
Body weight, blood glucose and basal hemodynamic 
parameters
STZ-diabetic rats presented significant hyperglycemia and
low body weight gain as compared to control rats. Treat-
ment with insulin normalized blood glucose levels and
body weight gain. These findings are in agreement with
the literature which indicates that insulin normalizes the
metabolic control of diabetic rats [13,15].
From the hemodynamic point of view STZ-diabetic rats
presented significant hypotension and bradycardia which
are also in line with previous findings from the literature
[9,10,17-20]. It is well documented that this resting
bradycardia is associated with cardiac sympathetic nerve
impairment [9,10,13]. However, studies from isolated
heart preparations have indicated that STZ-induced diabe-
tes might be associated with decreased intrinsic heart rate
as well [17,21]. Hypotension has been ubiquitously
described in STZ-diabetic rats [9,10,13,19,20] and the fol-
lowing mechanisms are postulated as responsible for this
hemodynamic outcome: 1) decreased cardiac output [5];
2) hypovolemia due to osmotic diuresis [23]; 3) impair-
ment of sympathetic innervation of heart and vessels
[10,21].Cardiovascular Diabetology 2006, 5:26 http://www.cardiab.com/content/5/1/26
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Myocardial Contractility and Relaxation
Despite a number of studies either in anesthetized ani-
mals or in vitro preparations, to our knowledge, the
present study is the first to describe in conscious STZ-dia-
betic rats, both, attenuated basal inotropism (+dP/dtmax),
as well as attenuated basal lusitropism (-dP/dtmax). Myo-
cardial dysfunction is an important feature that might be
associated with a number of intrinsic alterations of cardiac
myocytes [5]. There are several studies in vivo (anesthe-
tized animals) and in vitro (Langhendorff and isolated
myocytes) showing an impairment on Ca++ homeostasis
and Ca++signaling in diabetes [5,6,23]. The literature
reports studies of myocardial contractility in diabetes
showing conspicuous diastolic dysfunction [2,24]. Fein et
al [2] described substantial deleterious effects of diabetes
in cardiac papillary muscles of rats. The most significant
abnormalities involved delay of the relaxation process,
slow relaxation ratio and delay in peak ratio of isometric
and isotonic relaxation. Nevertheless, recent studies dem-
onstrated reduced expression of sarcoplasmic reticulum
calcium-ATPase and sodium-calcium exchanger [6,23].
Decreased basal contractility in the STZ-diabetic rats, as
demonstrated by means of low +dP/dtmax, was also
observed in the present study. Reports in the literature
have demonstrated myocardial dysfunction in spontane-
ously diabetic rats [5]. It has been suggested that this myo-
cardial derangement is typical of the cardiac myocyte of
the diabetic rat, which shows significant reduction of cell
shortening and attenuation of the velocities of cell short-
ening and relaxation, associated with low levels of
cytosolic Ca++. The decrease in inward Ca++ current, which
triggers the ryanodine Ca++ channel to release Ca++ [6,25]
from the sarcoplasmic reticulum, could be also an impor-
tant factor to explain the decrease of +dP/dtmax. Further-
more, it was reported that diabetes reduces ryanodine
sensitive Ca++ channel expression of cardiac myocytes in
rats [6,23]. Even though the methodological approach
used in the present study does not allow to assess the
mechanism responsible for the alterations of myocardial
function in conscious STZ-diabetic rats, the literature
shows a number of studies dealing with impairment of
either Ca++ signaling or sarcoplasmic reticulum function
[5,26], which might explain, at least partially, the findings
of the present study.
An impairment of sympathetic innervation of the heart,
frequently observed in diabetes [10,19,21], should be also
taken into consideration in the impairment of myocardial
contractility found in STZ-diabetic rats.
In addition, in the present study, treatment with insulin
prevented the occurrence of alterations caused by diabe-
tes, i.e. bradycardia, hypotension and low +dP/dtmax and
low -dP/dtmax. Several studies demonstrated that insulin
can prevent, or even reverse, the derangements caused by
chronic diabetes [12,13]. Nevertheless, the mechanism
responsible for this protective effect is still unknown,
because diabetes is a long-standing metabolic disorder
with several outcomes. It has been demonstrated in nor-
mal cardiac myocytes that insulin speeds the glucose
transport into the cell [27]. However, it has been demon-
strated also that insulin promotes a positive inotropic
effect independent of glucose uptake [28]. According to
Stroedter et al. [15] the improvement of cardiac perform-
ance caused by subcutaneous administration of insulin,
or by intraportal islet transplantation, follows the normal-
ization of cardiac metabolism. This finding suggests that
the dysfunction of the heart observed in diabetes may be
Table 1: Weight and blood glucose levels.
Weight Blood Glucose
1st day 3rd day 15th day 3rd day 15th day
Control 323 ± 10 344 ± 8 446 ± 9‡ 107 ± 3 109 ± 3
STZ 348 ± 13 330 ± 15 296 ± 6†§ 453 ± 18* 444 ± 17§
STZ + Insulin 303 ± 15 335 ± 3 416 ± 11‡ 464 ± 35* 101 ± 3
Weight (g) and blood glucose (mg/dL) of control, STZ-diabetic and STZ-diabetic rats treated with insulin (STZ+Insulin). Data are reported as mean 
± SEM. *P < 0.001 as compared to control group; †P < 0.05 as compared to 1st day; ‡P < 0.001 as compared to 1st and 3rd day; §P < 0.001 as 
compared to control and STZ+Insulin group.
Table 2: Basal hemodynamic parameters
MAP HR +dP/dtmax -dP/dtmax
Control 103 ± 3 359 ± 5 12676 ± 723 -8207 ± 339
STZ 91 ± 3* 312 ± 7* 9512 ± 437* -5763 ± 422*
STZ + Insulin 105 ± 4 357 ± 11 13943 ± 863 -8985 ± 315
Mean arterial pressure (MAP; mmHg), heart rate (HR bpm), maximum rate of isovolumic pressure development (+dP/dtmax, mmHg/s) and 
maximum rate of isovolumic pressure decay (-dP/dtmax, mmHg/s) of control, STZ-diabetic and STZ-diabetic rats treated with insulin (STZ+Insulin). 
Data are reported as mean ± SEM. * P < 0.05 as compared to control and STZ+Insulin group.Cardiovascular Diabetology 2006, 5:26 http://www.cardiab.com/content/5/1/26
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caused by conspicuous alterations of myocardial metabo-
lism caused by insulin deficiency, which can be reversed
by means of exogenous replacement of the hormone.
β1-Adrenergic Receptor Stimulation with Dobutamine
Two dosages of dobutamine, i.e. 1 and 15 μg/kg were used
to promote pharmacological stimulation of myocardial
contractility, relaxation and heart rate without the effect of
anesthesia. STZ-diabetic rats exhibited greater inotropic,
lusitropic as well tachycardic response to the lower dosage
(1.0 μg/kg) of β1-adrenergic receptor agonist as compared
to control rats and STZ-diabetic rats treated with insulin.
These findings might be explained, at least partially, by
means of an up-regulation of β1-adrenergic receptors
exhibited by STZ-diabetic rats, even though this hypothe-
sis deserves better investigation. Previous study from our
laboratory has demonstrated that even short term (5 days)
STZ-diabetes produces attenuation of the sympathetic
drive [10]. In addition, it has been already described that
sympathetic impairment [9,20] during the development
of diabetes, leads to an increase in the number of β1-
adrenergic receptors [29,30]. However, this up-regulation
seems to be of short duration, because there is a body of
evidence showing a decrease in the number of β1-adrener-
Responses of +dP/dtmax and -dP/dtmax to β1-adrenergic stimulation with dobutamine (1 and 15 μg/kg) in conscious control  (treated with vehicle) rats, and conscious diabetic rats obtained by means of streptozotocin (STZ), treated (STZ+Insulin), or  not (STZ-diabetic), with insulin Figure 1
Responses of +dP/dtmax and -dP/dtmax to β1-adrenergic stimulation with dobutamine (1 and 15 μg/kg) in conscious control 
(treated with vehicle) rats, and conscious diabetic rats obtained by means of streptozotocin (STZ), treated (STZ+Insulin), or 
not (STZ-diabetic), with insulin. Data are reported as means ± SEM. *P < 0.05 compared to the other groups stimulated with 1 
μg/kg; +P < 0.05 compared to their counterparts stimulated with 1 μg/kg.Cardiovascular Diabetology 2006, 5:26 http://www.cardiab.com/content/5/1/26
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gic receptor is the predominant finding in chronic diabe-
tes [19,31,32]. On the other hand, there was no difference
among the three groups concerning the responses of heart
rate, +dP/dtmax and -dP/dtmax. to the higher dosage (15 μg/
kg) of dobutamine, indicating that this dosage was not
able to discriminate differences of cardiac function in con-
trol rats versus STZ-diabetic rats treated, or not, with insu-
lin, probably due to a saturation of β1-adrenergic
receptors [33].
Conclusion
The findings of the present study are in line with previous
reports from the literature [9,10,19,20], showing that STZ-
diabetes is characterized by bradycardia and hypotension.
However, the present study provides new data from con-
scious rats showing that the cardiomyopathy of this
pathophysiological condition was expressed by low indi-
ces of contractility and relaxation. In addition, it was also
demonstrated that these pathophysiological features were
Responses of heart rate and mean arterial pressure to β1-adrenergic stimulation with dobutamine (1 and 15 μg/kg) in conscious  control (treated with vehicle) rats, and conscious diabetic rats obtained by means of streptozotocin (STZ), treated (STZ+Insu- lin), or not (STZ-diabetic), with insulin Figure 2
Responses of heart rate and mean arterial pressure to β1-adrenergic stimulation with dobutamine (1 and 15 μg/kg) in conscious 
control (treated with vehicle) rats, and conscious diabetic rats obtained by means of streptozotocin (STZ), treated (STZ+Insu-
lin), or not (STZ-diabetic), with insulin. Data are reported as means ± SEM. *P < 0.05 compared to the other groups stimulated 
with 1 μg/kg; +P < 0.05 compared to their counterparts stimulated with 1 μg/kg.Cardiovascular Diabetology 2006, 5:26 http://www.cardiab.com/content/5/1/26
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prevented by the treatment with insulin. Furthermore, the
greater inotropic, lusitropic and tachycardic effect caused
by low dosage (1 μg/kg) of dobutamine in STZ-diabetic
rats might be explained by an up-regulation of β1-adren-
ergic receptors.
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